Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 17/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 17/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472588 | 0.89 | ALDH1A1 (0.53) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL15147603 | 0.85 | KDM4E (0.58) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL3475318 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4EHPGDUSP2CYP1A2 | |
| SCHEMBL3472610 | 0.81 | KDM4E (0.50) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL28464136 | 0.80 | KDM4E (0.60) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL13366929 | 0.80 | KDM4E (0.53) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL13366943 | 0.79 | KDM4E (0.51) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL3475191 | 0.78 | TGFBR1 (0.48) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL3473462 | 0.78 | SMN1; SMN2 (0.47) | ALDH1A1KDM4EGLAHPGDSMN1; SMN2 | |
| SCHEMBL3434425 | 0.75 | GRIN2B (0.50) | ALDH1A1USP2CYP1A2CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912190-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-12-16 | — | — | US | claimed |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-01 | — | — | US | claimed |
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8912190-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113461-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, KCNJ2, KCNH2 | ALDH1A1 503/4885KDM4E 1283/4885GLA 1927/4885 |
| US-20130197001-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | KCNH1, KCNJ2, KCNH2 | ALDH1A1 503/4885KDM4E 1283/4885GLA 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.